4.5 Review

Hypoxia and oxidative stress in breast cancer - Tumour hypoxia - therapeutic considerations

Journal

BREAST CANCER RESEARCH
Volume 3, Issue 5, Pages 328-331

Publisher

BIOMED CENTRAL LTD
DOI: 10.1186/bcr316

Keywords

bioreductive drugs; hypoxia; hypoxia responsive element; reductase enzymes

Categories

Funding

  1. Medical Research Council [G0500366] Funding Source: Medline

Ask authors/readers for more resources

Conclusive research has shown that regions of acute/chronic hypoxia, which exist within the majority of solid tumours, have a profound influence on the therapeutic outcome of cancer chemotherapy and radiotherapy and are a strong prognostic factor of disease progression and survival. A strong argument therefore exists for assessing the hypoxic fraction of tumours, prior to patient treatment, and to tailor this treatment accordingly. Tumour hypoxia also provides a powerful physiological stimulus that can be exploited as a tumour-specific condition, allowing for the rationale design of hypoxia-activated anticancer drugs or novel hypoxia-regulated gene therapy strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available